"Macrophage immunotherapy" CT-0508 treatment of solid tumors: better than traditional cell therapy.
-
Last Update: 2020-07-30
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
carISMA Therapeutics, !---- a biopharmaceutical company focused on the development of immunotherapy, today announced that the U.S. Food and Drug Administration (FDA) has approved the application for a new research drug (IND) for its main candidate drug, CT-0508, which targets human epidermal growth factor receptor 2 (HER2) inaniated antigen receptor macrophage (CAR-M) therapy.based on the IND, CARISMA plans to initiate Phase I clinical trials for CT-0508 treatment for patients with recurrent or metastatic HER2 overexpression solid tumors. "This IND approval marks the first successful entry of engineered macrophages into clinical trials, and the approval of CT-0508 to clinical trials is an important milestone in the field of cancer immunotherapy," said Steven Kelly, CEO ofCARISMA Therapeutics.has historically faced key challenges in the treatment of solid tumors, including transport restrictions to tumor sites, immunosuppressive tumor microenvironments, and heterogeneous expression of tumor-related antigens, carISMA preclinical data suggest that CAR-M therapy can overcome these challenges..
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
